There’s a resurgence of interest in psychedelic plants and drugs, human studies of their benefits in treating mental health conditions, and favorable publicity about their therapeutic potential. Examples include: MDMA for PTSD; Psilocybe mushrooms and psilocybin for OCD, depression, and spiritual growth; ayahuasca for a wide range of physical and psychological ailments; LSD and psilocybin as adjuncts to end-of-life care in terminal cancer; and iboga and ibogaine for the treatment of opioid and alcohol addiction. Presenters will also discuss the new practice of microdosing with LSD and psilocybin to enhance creativity and productivity. All of these substances have very low toxicity compared to widely used medications. Their effects depend on dosage, set, and setting, as well as the experience and skill of therapists.